{"schema_version":"secwatch.filing_event.v1","accession":"0000917520-24-000059","form_type":"8-K","ticker":"IART","cik":"0000917520","company_name":"INTEGRA LIFESCIENCES HOLDINGS CORP","filed_at":"2024-05-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:22.442748+00:00","generated_at":"2026-06-02T22:44:01.541283+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Q1 revenues $368.9M (-3.1%); GAAP EPS $(0.04); adj. EPS $0.55; guidance raised on Acclarent","bullets":["Q1 revenues $368.9M (-3.1% reported, -2.5% organic; +1.6% organic ex-Boston); GAAP net loss $3.3M ($(0.04)/share) vs net income $24.2M ($0.29) prior year.","Adjusted EPS $0.55 vs $0.74 prior year; adjusted EBITDA $71.8M (19.5% rev) vs $92.3M (24.2%).","Acclarent acquisition closed April 1; FY2024 revenue guidance raised to $1.672-1.687B, adj. EPS guidance $3.01-3.11.","Tissue Technologies revenue fell 15.3% driven by Boston recall; removing SurgiMend/PriMatrix relaunch from guidance due to audit findings.","Codman Specialty Surgical grew 3.3% reported (4.4% organic); Neurosurgery up 6.3% organically, Instruments down 2.0%."],"urls":{"canonical":"https://secwatch.observer/filing/0000917520-24-000059","json":"https://secwatch.observer/filing/0000917520-24-000059.json","markdown":"https://secwatch.observer/filing/0000917520-24-000059.md","text":"https://secwatch.observer/filing/0000917520-24-000059.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/917520/000091752024000059/0000917520-24-000059-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/917520/000091752024000059/iart-20240506.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T22:44:01.541283+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"6dbea63532d5595e9c32982658871baeeab9440a","claim":"INTEGRA LIFESCIENCES HOLDINGS CORP reported the quarter ended March 31, 2024 results: revenue $368.9 million, net income $(3.3) million, EPS $(0.04) per diluted share. Guidance raised.","evidence_excerpt":"Total reported revenues of $368.9 million declined 3.1% on a reported basis and declined 2.5% on an organic basis compared to the prior year. Organic growth excluding Boston was 1.6%. Revenue exceeded the outlook the Company provided in February. The Company reported GAAP gross margin of 56.1%, compared to 61.1% in the first quarter of 2023. Adjusted gross margin was 64.4%, compared to 67.3% in the prior year. Adjusted EBITDA for the first quarter of 2024 was $71.8 million, or 19.5% of revenue, compared to $92.3 million, or 24.2% of revenue, in the prior year. The Company reported a GAAP net loss of $(3.3) million, or $(0.04) per diluted share, in the first quarter of 2024, compared to a GAAP net income of $24.2 million, or $0.29 per diluted share, in the prior year.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/917520/000091752024000059/0000917520-24-000059-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended March 31, 2024"},{"label":"Revenue","value":"$368.9 million"},{"label":"Net income","value":"$(3.3) million"},{"label":"EPS","value":"$(0.04) per diluted share"},{"label":"Guidance","value":"raised"},{"label":"Result","value":"reported results"}]}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}